<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03029104</url>
  </required_header>
  <id_info>
    <org_study_id>CXL-005</org_study_id>
    <nct_id>NCT03029104</nct_id>
  </id_info>
  <brief_title>COLLAGEN CROSS-LINKING WITH ULTRAVIOLET-A IN ASYMMETRIC CORNEAS</brief_title>
  <official_title>COLLAGEN CROSS-LINKING WITH ULTRAVIOLET-A IN ASYMMETRIC CORNEAS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cxlusa</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cxlusa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess changes in visual acuity and corneal symmetry after corneal collagen
      cross-linking (CXL) of asymmetric corneas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the results of Corneal Collagen Crosslinking (CXL) in patients with
      conditions that include keratoconus, forme fruste keratoconus, post-LASIK ectasia, pellucid
      marginal degeneration, forme fruste pellucid marginal degeneration, diurnal fluctuation
      post-radial keratotomy, or Terrien's marginal degeneration. This is an outcomes study, all
      patients receive treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">January 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Best corrected visual acuity (BCVA) will be evaluated by an observer who is masked as to the treatment protocol to which study subjects have been assigned.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Corrected Distance Visual Acuity (CDVA)</measure>
    <time_frame>6 months</time_frame>
    <description>Change in corrected distance visual acuity (CDVA) compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uncorrected distance visual acuity (UCVA)</measure>
    <time_frame>6 months</time_frame>
    <description>Change in uncorrected distance visual acuity (UCVA) compared to baseline
Secondary: Change at 6 months as compared to baseline in:
Uncorrected distance visual acuity
KMax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KMax</measure>
    <time_frame>6 months</time_frame>
    <description>Change in Kmax compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Keratoconus</condition>
  <condition>Corneal Diseases</condition>
  <condition>Eye Diseases</condition>
  <condition>Photosensitizing Agents</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using CXLO Corneal Strengthening Solution and a UVA irradiance of 4 mW/cm2 cycled On/Off at 15 second intervals for 20 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using CXLO Corneal Strengthening Solution and a UVA irradiance of 6 mW/cm2 cycled On/Off at 15 second intervals for 20 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using CXLO Corneal Strengthening Solution and a UVA irradiance of 4 mW/cm2 cycled On/Off at 15 second intervals for 30 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CXLO Corneal Strengthening Solution and UVA Illumination</intervention_name>
    <description>CXLO Corneal Strengthening Solution</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A diagnosis of at least one of the following conditions:

               1. Keratoconus

               2. Forme fruste keratoconus

               3. Post-LASIK ectasia

               4. Pellucid marginal degeneration

               5. Forme fruste pellucid marginal degeneration

               6. Diurnal fluctuation post-radial keratotomy

               7. Terrien's marginal degeneration

        Exclusion Criteria:

          1. Corneal thickness &lt; 375 microns measured by ultrasound or Pentacam.

          2. Contraindications or hypersensitivities to any study medications or their components.

          3. Pregnancy or breastfeeding.

          4. Any history of herpes simplex corneal disease in an eye to be treated.

          5. Nystagmus or any other condition that would, in the judgement of the investigator,
             prevent a steady gaze during the treatment.

          6. Inability to cooperate with diagnostic tests.

          7. Enrollment in another ophthalmic clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregg J Berdy, MD, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ophthalmology Associates, St. Louis, MO</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Debi S Gravemann, RN</last_name>
    <phone>(314) 966-3377</phone>
    <email>dg@cxlusa.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roxanne Littner, MS</last_name>
    <phone>(202) 791-0374</phone>
    <email>roxannelittner@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Schwartz Laser Eye Center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay L Schwartz, D.O.</last_name>
      <phone>480-483-3937</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Goodman Eye Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Symon</last_name>
      <phone>415-474-3333</phone>
    </contact>
    <investigator>
      <last_name>Dan Goodman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cornea Consultants of Colorado</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120-4508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Damiano</last_name>
      <phone>303-730-0404</phone>
    </contact>
    <investigator>
      <last_name>S. Lance Forstot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Woolfson Eye Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doyle Stulting, MD, PhD</last_name>
      <phone>770-740-0233</phone>
    </contact>
    <investigator>
      <last_name>Doyle Stulting, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johathan M Woolfson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chicago Cornea Consultants, Ltd.</name>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <zip>60169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jim Nykaza</last_name>
      <phone>847-432-6010</phone>
    </contact>
    <investigator>
      <last_name>Parag A Majmudar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Randy J Epstein, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria E Rosselson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Associates</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregg J Berdy, MD, FACS</last_name>
      <phone>314-966-5000</phone>
    </contact>
    <contact_backup>
      <last_name>Debi Gravemann, RN</last_name>
      <phone>(314) 966-3377</phone>
      <email>dg@cxlusa.com</email>
    </contact_backup>
    <investigator>
      <last_name>Gregg J Berdy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Eye Clinic</name>
      <address>
        <city>Brecksville</city>
        <state>Ohio</state>
        <zip>44141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chandra Barnett</last_name>
      <phone>216-503-6535</phone>
      <email>cbarnett@clearchoicelaser.com</email>
    </contact>
    <investigator>
      <last_name>Shamik Bafna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cornea Associates of Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Raines</last_name>
      <phone>214-692-0146</phone>
    </contact>
    <investigator>
      <last_name>Brad Bowman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2017</study_first_submitted>
  <study_first_submitted_qc>January 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2017</study_first_posted>
  <last_update_submitted>July 14, 2017</last_update_submitted>
  <last_update_submitted_qc>July 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Keratoconus</keyword>
  <keyword>Forme fruste keratoconus</keyword>
  <keyword>Post-LASIK ectasia</keyword>
  <keyword>Pellucid marginal degeneration</keyword>
  <keyword>Forme fruste pellucid marginal degeneration</keyword>
  <keyword>Diurnal fluctuation post-radial keratotomy</keyword>
  <keyword>Terrien's marginal degeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Keratoconus</mesh_term>
    <mesh_term>Corneal Diseases</mesh_term>
    <mesh_term>Dermatitis, Phototoxic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

